Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

2000 breast cancer patients to help Fine-Tune treatment decisions

NCT ID NCT07389408

Knowledge-focused Sponsor: National and Kapodistrian University of Athens Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 2000 people with early-stage, hormone-sensitive breast cancer to see how doctors decide on treatments, especially when using a test called EndoPredict. The goal is to track long-term outcomes like cancer return and survival over 5 to 10 years. No new treatments are tested—just observation of real-world care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 2,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2025

Expected to finish

Dec 2038

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

All subjects diagnosed with invasive breast cancer, pT1-pT3, with 0 to 3 positive axillary lymph nodes, ER-positive, HER2-negative, that have not received neo-adjuvant chemotherapy and therefore are eligible for EndoPredict® testing.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years old. * Histological diagnosis of invasive breast cancer. * T1-T3 tumor size. * 0-3 positive axillary lymph nodes. * Documented ER-positive tumor by immunohistochemistry (≥1% or Allred Score: ≥3/8 or H-score: ≥50/ 300) * Documented HER2-negative tumor by immunohistochemistry and/or in situ hybridization * Subject with signed and dated informed consent form. Exclusion Criteria: * History of another primary malignancy within the last 5 years, except for resected non-melanoma skin cancer. * Pre-operative chemotherapy administered. * Subject without signed and dated informed consent form.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast adenocarcinoma breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast adenocarcinoma Breast cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    13 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • "Apollonio-Theotokos" General Clinic, Department of Surgery

    RECRUITING

    Larissa, Greece

  • "Elena Venizelou" General Hospital, Department of Surgery

    RECRUITING

    Athens, Greece

  • "Prolipsis" Center, Breast Unit

    RECRUITING

    Athens, Greece

  • General Hospital of Trikala, Breast Surfery Dept.

    RECRUITING

    Trikala, Greece

  • Henry Dunant Hospital Center, 3rd Breast Surgical Department

    RECRUITING

    Athens, Greece

  • IASO General Clinic, 2nd Breast Clinic

    RECRUITING

    Marousi, Greece

  • IASO Thessalias General Clinic, Breast Surgery Department

    RECRUITING

    Larissa, Greece

  • Laiko Hospital, National and Kapodistrian University of Athens, Medical School

    RECRUITING

    Athens, Greece

  • MITERA, 1st Breast Clinic

    RECRUITING

    Marousi, Greece

  • Mediterraneo Hospital, Breast Clinic

    RECRUITING

    Athens, Greece

  • Metropolitan General Hospital, 3rd Breast Clinic

    RECRUITING

    Cholargós, Greece

  • Metropolitan General Hospital, 4th Breast Clinic

    RECRUITING

    Cholargós, Greece

  • Thessaloniki Bioclinic Hospital, Breast Unit

    RECRUITING

    Thessaloniki, Greece

More trials for these conditions

Other studies related to the condition(s) this trial covers.